Meta-analysis of Molteno glaucoma implants and Ahmed glaucoma valves: insights into efficacy and safety for complex glaucoma.

Autor:	Raja A; Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan., Bhimani S; Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan., Alim Ur Rahman H; Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan., Salman M; Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan., Saeed Shaikh A; Ziauddin Medical College, Ziauddin University, Karachi, Pakistan., Raja S; Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan., Zafar Sayeed B; Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan., Feroze A; Department of Medicine, Jinnah Postgraduate Medical Centre, Karachi, Pakistan., Ahmed M; Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan.
Jazyk:	angličtina
Zdroj:	Frontiers in ophthalmology [Front Ophthalmol (Lausanne)] 2023 Dec 11; Vol. 3, pp. 1307439. Date of Electronic Publication: 2023 Dec 11 (Print Publication: 2023).
DOI:	10.3389/fopht.2023.1307439
Abstrakt:	Background: Glaucoma is a leading cause of irreversible blindness globally and for decades, Molteno and Ahmed glaucoma implants, operating on different mechanisms, have been used to treat complicated glaucoma with varying success. Objective: To assess the safety and efficacy of the Molteno glaucoma implant (MGI) versus the Ahmed glaucoma valve (AGV) in patients with complicated glaucoma. Methods: We comprehensively searched PubMed, Google Scholar, Cochrane Library and Science Direct) from inception till July 2023 and studies comparing patients with MGI and those with AGV in patients with complicated glaucoma. The primary outcome was intra-ocular pressure reduction at different time intervals. Secondary outcomes included surgical success rate, hypertensive phase, anti-glaucoma medication (AGM) and total complications. Results: In this meta-analysis, four studies were included with a patient population of 257 with refractory, neovascular or advanced uncontrolled glaucoma. Postoperative intra-ocular pressure reduction did not show significant difference between the two groups (MD: -1.34, 95% CI [-2.78, 0.09]). From the secondary outcomes, surgical success rate (RR: 0.88, 95% CI [0.51,1.53]), hypertensive phase (RR: 0.74, 95% CI [0.39,1.40]) were insignificant. Postoperative anti-glaucoma medication (MD: -0.07, 95% CI [-0.79, -0.65] and total complications (RR:1.36, 95% CI [1.07, 1.72]) were significant. Conclusion: No significant difference was observed between the patients with MGI and AGV for the primary outcome. From the secondary outcome, AGV was associated with reduced anti-glaucoma medication use and significantly lowered the number of complications. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=475539, identifier CRD42023475539. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Raja, Bhimani, Alim Ur Rahman, Salman, Saeed Shaikh, Raja, Zafar Sayeed, Feroze and Ahmed.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu